Aug 13, 2021 5:30 am EDT Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
Aug 11, 2021 4:05 pm EDT Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
Aug 11, 2021 5:30 am EDT Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
Aug 3, 2021 5:30 am EDT Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
Jul 22, 2021 9:35 am EDT Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
Jun 29, 2021 5:30 am EDT Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
Jun 3, 2021 5:30 am EDT Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
Jun 2, 2021 5:30 am EDT Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference
May 27, 2021 4:05 pm EDT Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 25, 2021 8:30 am EDT Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offering